To lift itself from the bottom quartile of clinical trial performance, Merck Serono S.A. is harnessing the expertise of CRO Quintiles Transnational Corp. A five-year exclusive deal will bring Quintiles staff to the table from clinical strategy through execution and make the CRO responsible for helping avoid expensive delays routinely caused by problems like poor enrollment.

If the new model performs as intended, Merck Serono should be able to conduct trials faster and more successfully, without spending more money to do it.